IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: In support of this, our previous finding highlighted a substantial impact of tocilizumab (an IL-6 inhibitor) on the recovery of CML-impaired zebrafish swimming activity, underscoring a pivotal contribution of IL-6-mediated inflammation behind the CML-induced acute paralysis.